In silico and in vitro methods to identify ebola virus VP35-dsRNA inhibitors

Jason G. Glanzer, Brendan M. Byrne, Aaron M. McCoy, Ben J. James, Joshua D. Frank, Gregory G Oakley

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Ebola virus continues to be problematic as sporadic outbreaks in Africa continue to arise, and as terrorist organizations have considered the virus for bioterrorism use. Several proteins within the virus have been targeted for antiviral chemotherapy, including VP35, a dsRNA binding protein that promotes viral replication, protects dsRNA from degradation, and prevents detection of the viral genome by immune complexes. To augment the scope of our antiviral research, we have now employed molecular modeling techniques to enrich the population of compounds for further testing in vitro. In the initial docking of a static VP35 structure with an 80,000 compound library, 40 compounds were selected, of which four compounds inhibited VP35 with IC50 <200 μM, with the best compounds having an IC50 of 20 μM. By superimposing 26 VP35 structures, we determined four aspartic acid residues were highly flexible and the docking was repeated under flexible parameters. Of 14 compounds chosen for testing, five compounds inhibited VP35 with IC50 <200 μM and one compound with an IC50 of 4 μM. These studies demonstrate the value of docking in silico for enriching compounds for testing in vitro, and specifically using multiple structures as a guide for detecting flexibility and provide a foundation for further development of small molecule inhibitors directed towards VP35.

Original languageEnglish (US)
Pages (from-to)5388-5392
Number of pages5
JournalBioorganic and Medicinal Chemistry
Volume24
Issue number21
DOIs
StatePublished - Nov 1 2016

Fingerprint

Viruses
Computer Simulation
Inhibitory Concentration 50
Antiviral Agents
Testing
Bioterrorism
Molecular modeling
Chemotherapy
Ebolavirus
Antigen-Antibody Complex
Aspartic Acid
Viral Genome
Carrier Proteins
Genes
Libraries
Disease Outbreaks
Degradation
Molecules
Organizations
Drug Therapy

Keywords

  • Ebola
  • Inhibitor
  • Innate immune response
  • Molecular dynamic modeling
  • VP35

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

In silico and in vitro methods to identify ebola virus VP35-dsRNA inhibitors. / Glanzer, Jason G.; Byrne, Brendan M.; McCoy, Aaron M.; James, Ben J.; Frank, Joshua D.; Oakley, Gregory G.

In: Bioorganic and Medicinal Chemistry, Vol. 24, No. 21, 01.11.2016, p. 5388-5392.

Research output: Contribution to journalArticle

Glanzer, Jason G. ; Byrne, Brendan M. ; McCoy, Aaron M. ; James, Ben J. ; Frank, Joshua D. ; Oakley, Gregory G. / In silico and in vitro methods to identify ebola virus VP35-dsRNA inhibitors. In: Bioorganic and Medicinal Chemistry. 2016 ; Vol. 24, No. 21. pp. 5388-5392.
@article{d43bd4f327514931a28b7eb5bc789b66,
title = "In silico and in vitro methods to identify ebola virus VP35-dsRNA inhibitors",
abstract = "Ebola virus continues to be problematic as sporadic outbreaks in Africa continue to arise, and as terrorist organizations have considered the virus for bioterrorism use. Several proteins within the virus have been targeted for antiviral chemotherapy, including VP35, a dsRNA binding protein that promotes viral replication, protects dsRNA from degradation, and prevents detection of the viral genome by immune complexes. To augment the scope of our antiviral research, we have now employed molecular modeling techniques to enrich the population of compounds for further testing in vitro. In the initial docking of a static VP35 structure with an 80,000 compound library, 40 compounds were selected, of which four compounds inhibited VP35 with IC50 <200 μM, with the best compounds having an IC50 of 20 μM. By superimposing 26 VP35 structures, we determined four aspartic acid residues were highly flexible and the docking was repeated under flexible parameters. Of 14 compounds chosen for testing, five compounds inhibited VP35 with IC50 <200 μM and one compound with an IC50 of 4 μM. These studies demonstrate the value of docking in silico for enriching compounds for testing in vitro, and specifically using multiple structures as a guide for detecting flexibility and provide a foundation for further development of small molecule inhibitors directed towards VP35.",
keywords = "Ebola, Inhibitor, Innate immune response, Molecular dynamic modeling, VP35",
author = "Glanzer, {Jason G.} and Byrne, {Brendan M.} and McCoy, {Aaron M.} and James, {Ben J.} and Frank, {Joshua D.} and Oakley, {Gregory G}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.bmc.2016.08.065",
language = "English (US)",
volume = "24",
pages = "5388--5392",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "21",

}

TY - JOUR

T1 - In silico and in vitro methods to identify ebola virus VP35-dsRNA inhibitors

AU - Glanzer, Jason G.

AU - Byrne, Brendan M.

AU - McCoy, Aaron M.

AU - James, Ben J.

AU - Frank, Joshua D.

AU - Oakley, Gregory G

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Ebola virus continues to be problematic as sporadic outbreaks in Africa continue to arise, and as terrorist organizations have considered the virus for bioterrorism use. Several proteins within the virus have been targeted for antiviral chemotherapy, including VP35, a dsRNA binding protein that promotes viral replication, protects dsRNA from degradation, and prevents detection of the viral genome by immune complexes. To augment the scope of our antiviral research, we have now employed molecular modeling techniques to enrich the population of compounds for further testing in vitro. In the initial docking of a static VP35 structure with an 80,000 compound library, 40 compounds were selected, of which four compounds inhibited VP35 with IC50 <200 μM, with the best compounds having an IC50 of 20 μM. By superimposing 26 VP35 structures, we determined four aspartic acid residues were highly flexible and the docking was repeated under flexible parameters. Of 14 compounds chosen for testing, five compounds inhibited VP35 with IC50 <200 μM and one compound with an IC50 of 4 μM. These studies demonstrate the value of docking in silico for enriching compounds for testing in vitro, and specifically using multiple structures as a guide for detecting flexibility and provide a foundation for further development of small molecule inhibitors directed towards VP35.

AB - Ebola virus continues to be problematic as sporadic outbreaks in Africa continue to arise, and as terrorist organizations have considered the virus for bioterrorism use. Several proteins within the virus have been targeted for antiviral chemotherapy, including VP35, a dsRNA binding protein that promotes viral replication, protects dsRNA from degradation, and prevents detection of the viral genome by immune complexes. To augment the scope of our antiviral research, we have now employed molecular modeling techniques to enrich the population of compounds for further testing in vitro. In the initial docking of a static VP35 structure with an 80,000 compound library, 40 compounds were selected, of which four compounds inhibited VP35 with IC50 <200 μM, with the best compounds having an IC50 of 20 μM. By superimposing 26 VP35 structures, we determined four aspartic acid residues were highly flexible and the docking was repeated under flexible parameters. Of 14 compounds chosen for testing, five compounds inhibited VP35 with IC50 <200 μM and one compound with an IC50 of 4 μM. These studies demonstrate the value of docking in silico for enriching compounds for testing in vitro, and specifically using multiple structures as a guide for detecting flexibility and provide a foundation for further development of small molecule inhibitors directed towards VP35.

KW - Ebola

KW - Inhibitor

KW - Innate immune response

KW - Molecular dynamic modeling

KW - VP35

UR - http://www.scopus.com/inward/record.url?scp=84991490606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991490606&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2016.08.065

DO - 10.1016/j.bmc.2016.08.065

M3 - Article

VL - 24

SP - 5388

EP - 5392

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 21

ER -